Profile picture

Doctor Satoshi Yasuda

Tohoku University, Sendai (Japan)
Membership: FESC Member
Follow
Biography
EDUCATION 1987 M.D. Tohoku University School of Medicine 2000 Ph.D. Tohoku University School of Medicine PROFESSIONAL EXPERIENCE 2006 – 2007 Assistant Professor and Chief of Coronary Care Unit Tohoku University Hospital Department of Cardiovascular Internal Medicine Sendai, Miyagi, Japan 2007 – 2011 Associate Professor in Cardiovascular Medicine Tohoku University School of Medicine Sendai, Miyagi, Japan 2011 – 2016, Jan Chairman National Cerebral and Cardiovascular Center Department of Cardiovascular Medicine Osaka, Japan 2016. Feb – 2020.Jul Deputy Director General National Cerebral and Cardiovascular Center Department of Cardiovascular Medicine Osaka, Japan 2020. Aug – present Professor and Chairman Tohoku University Graduate School of Medicine Department of Cardiovascular Medicine Sendai, Miyagi, Japan
Logo ESC

Contributor content

Antithrombotic monotherapy for stable coronary artery disease and atrial fibrillation patients with and without prior coronary artery revascularization: Insights from the AFIRE trial
Presentation
Antithrombotic monotherapy for stable coronary artery disease and atrial fibrillation patients with and without prior coronary artery revascularization: Insights from the AFIRE trial
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
Presentation
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
Ethnic differences in the response to anti-thrombotic drugs.
Presentation
Ethnic differences in the response to anti-thrombotic drugs.
AFIRE trial: “less is more” lesson from Japan to the world.
Presentation
AFIRE trial: “less is more” lesson from Japan to the world.
The Japanese AMI registry (JAMIR) and JROAD Registries: How to set up a national registry.
Presentation
The Japanese AMI registry (JAMIR) and JROAD Registries: How to set up a national registry.
Intervention - Asian Perspective.
Presentation
Intervention - Asian Perspective.
AFIRE - Rivaroxaban monotherapy versus combination therapy in patients with atrial fibrillation and stable coronary artery disease
Presentation
AFIRE - Rivaroxaban monotherapy versus combination therapy in patients with atrial fibrillation and stable coronary artery disease

ESC 365 is supported by